Merck KGaA strikes $3.9bn deal for SpringWorks
Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire…
Oncology
-
-
China approves InnoCare Pharma’s BTK inhibitor for lymphoma
China’s National Medical Products Administration (NMPA) has approved InnoCare Pharma’s Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for use as a…
-
Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an…
-
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
The US Food and Drug Administration (FDA) has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal…
-
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp,…
-
UK’s MHRA authorises GSK’s Blenrep for multiple myeloma treatment
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM). This authorisation…
-
Reveal Genomics and Ona link on ONA-255 development for cancer
Reveal Genomics and Ona Therapeutics have formed a strategic partnership to expedite the clinical development of the antibody-drug conjugate (ADC),…
-
Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial
Patients with an advanced type of skin melanoma in England will be given expedited access to a new vaccine being…
-
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with…
-
AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a…
